Uncategorized

Santhera Starts Collaboration in Gene Therapy Research for Congenital Muscular Dystrophy with the Biozentrum, University of Basel, Co-Financed by Innosuisse

Posted on by Olivier
21
May

Santhera Pharmaceuticals announces on May 21st its collaboration with the Biozentrum of the University of Basel to advance gene therapy research for the treatment of LAMA2-deficient congenital muscular dystrophy (LAMA2 MD or MDC1A). The program is supported by public funding for innovation in Switzerland through a grant from Innosuisse – the Suisse Innovation Agency. Innosuisse and Santhera will jointly invest CHF 1.2 million into this preclinical research collaboration.

For further information, see Santhera PR (http://www.santhera.com/assets/files/press-releases/2019-05-21_GenTher_Innosuisse_e_final.pdf)

[section class="login-section" visibility="hide-for-small" padding="80px"]
[/section] [section label="one" class="login-signup-section" bg="363" bg_size="original" bg_pos="50% 0%" visibility="hide-for-small"]
[/section] [section class="login-section" visibility="show-for-small"]
[/section] [section label="one" bg_color="#194295" visibility="show-for-small"]
[/section]